Wuhan YZY Biopharma Co., Ltd.

2496

CNE1000063C4

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:13 09/06/2026 pm IST			5-day change	1st Jan Change
4.200 ^HKD	0.00%		-2.33%	-47.63%

07/05	Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China	MT
07/05	Wuhan YZY Biopharma Co., Ltd. Announces Acceptance of New Drug Application for M701 for Treatment of Malignant Ascites by National Medical Products Administration	CI

Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China

Published on 05/07/2026 at 07:45 pm IST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Wuhan YZY Biopharma Co., Ltd.

07/05	Wuhan YZY Biopharma, Sino Biopharm Unit's Application for Ascites Drug Accepted in China	MT
07/05	Wuhan YZY Biopharma Co., Ltd. Announces Acceptance of New Drug Application for M701 for Treatment of Malignant Ascites by National Medical Products Administration	CI
07/05	Wuhan Yzy Biopharma Co says NDA for M701 accepted by NMPA for treatment of malignant ascites	RE
27/03	Wuhan YZY Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03/02	Wuhan Yzy Biopharma says M701 receives IND approval from FDA	RE
03/02	Wuhan YZY Biopharma Gets Trial Nod for Malignant Pleural Effusion Drug from US FDA	MT
03/02	Wuhan YZY Biopharma Co., Ltd. Announces M701 Receives Ind Approval from FDA	CI
23/01	Wuhan Yzy Biopharma says Wuhan Yiruide to buy land use right and building	RE
24/12	Wuhan Yzy Biopharma says Y225 receives IND approval from NMPA	RE
24/12	Wuhan YZY Biopharma Co., Ltd. Announces Investigational New Drug Application for Its Biosimilar Y225	CI
02/12	Wuhan YZY Biopharma's Trial Results for Tumor Drug Published in International Journal	MT
02/12	Wuhan YZY Biopharma Co., Ltd. Announces Phase II Data of M701 for Malignant Ascites Published in Experimental Hematology & Oncology	CI
19/25/19	Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Interim Data of M701 for Malignant Leural Effusion Presented at the ESMO Congress 2025	CI
26/25/26	Wuhan YZY Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25/25/25	Wuhan YZY Biopharma Co., Ltd. Announces Committee and Directorate Changes	CI

Chart Wuhan YZY Biopharma Co., Ltd.

Duration

Period

2496: Dynamic Chart

Wuhan YZY Biopharma Co Ltd is a China-based company mainly engaged in the discovery, development, and commercialization of new innovative drugs in the field of anti-tumor bispecific antibodies. The Company is committed to developing bispecific antibody (BsAb) based therapies for the treatment of cancer-related complications, cancer, and age-related eye diseases to address the medical needs in oncology and geriatric eye diseases. The Company's core product M701 is a recombinant BsAb that targets human cancer cell surface antigen EpCAM and human T cell surface antigen CD3. The Company's product pipeline also includes Y101D, Y332, Y225, and others.

Employees

106

Sector

Biotechnology & Medical Research

More about the company